These are the changes Lowercase Capital's Chris Sacca would like to see on Twitter's board.» Read More
The risk will make you queasy, but the reward might be worth it.
First, Pfizer gave up on its inhaled insulin Exubera, then NovoNordisk threw in the towel and now it looks like Lilly is going to bow out. Alkermes, which is working on a palm-sized product called, "AIR Insulin," put out a press release today saying it expects its partner on the device, Lilly, to decide next week that it will exit the deal. ALKS shares hit a new low on the news.
The stunning pay packages of executives at financial groups hammered by the U.S. mortgage crisis came in for stinging criticism from Democratic lawmakers and investor advocates at a congressional hearing Friday.
I thought I was finished with the post-Pfizer analyst meeting reaction with yesterday's post, but when an extraordinarily bearish 77-page research note from Credit Suisse big pharma analyst Catherine Arnold arrived in my inbox this morning, I had to do one more installment. She thinks Pfizer should buy Wyeth or Amgen...
Countrywide Financial CEO Angelo Mozilo told a congressional panel Friday that he is "extremely concerned" that recent tightening of mortgage underwriting criteria has gone too far.
The heads of three companies implicated in the mortgage crisis have been asked to explain how they collectively received hundreds of millions of dollars in compensation while their companies were losing money.
The CEO of this dying newspaper company is a one-man black hole for shareholder value.
This waste management play is money in the bank so long as Romano is at the helm.
Surprise, surprise. Another CEO could get a massive payout despite his terrible performance.
There's an opportunity to make money, and Cramer doesn't want investors missing it.
I'm in the press room at the midtown Manhattan hotel where Pfizer is holding its analyst meeting. There's just over half a dozen reporters here and we're nearly outnumbered by PR folks. As one of them remarked, the press turnout for an event like this just isn't what it used to be...
Here's something that should make you realize what crazy times we are living in: 9-year auto loans are popping up around the country. That's right, it wasn't a typo. Nine years! 108 months! Almost a third of the time used to pay off a conventional mortgage!
The day before Pfizer's analyst meeting tomorrow investors are not showing much love for the beaten-down Dow component. PFE's trading in the early going today at its lowest level since December 2005.
Amid the gloomy comments from auto executives at the Geneva Motor Show, the unveilings of several important new models are being overshadowed. Take the new Ford Fiesta. This compact car is being sold in Europe, but the design cues and architecture behind this car will be the underpinnings of compact cars the automaker will roll out in the U.S. in the future.
Expensive oil and a coal shortage will only push this stock higher, Cramer says.
On the eve of the make-or-break Texas-Ohio primaries for Sen. Hillary Clinton, she remains in first place in at least one "poll." The Center for Responsive Politics has updated its list of top pharmaceuticals/health products-industry money recipients based on the most recent campaign finance reports and the former First Lady edges out Sen. Barack Obama...
Fortress Investment Group came to market at private equity's peak. Too bad no one but the company knew the party was over.
It's Cramer's favorite of his Fab Five agriculture stocks. Don't miss this interview with the CEO.
Only 39 percent of big investors think the way U.S. companies reward top executives has helped improve corporate performance, and most believe that top managers have too much influence in setting their own pay, a new study has found.
German drugs and chemicals group Bayer missed fourth-quarter earnings expectations Thursday, sending shares 4.7 percent lower on the DAX, but CEO Werner Wenning told CNBC he remains optimistic about the company’s outlook for this year.